KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBIT: 2020-2025

Historic EBIT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$172.2 million.

  • Recursion Pharmaceuticals' EBIT fell 75.08% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 83.57%. This contributed to the annual value of -$479.0 million for FY2024, which is 36.83% down from last year.
  • Recursion Pharmaceuticals' EBIT amounted to -$172.2 million in Q3 2025, which was up 2.28% from -$176.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' EBIT registered a high of -$30.5 million during Q1 2021, and its lowest value of -$191.4 million during Q1 2025.
  • In the last 3 years, Recursion Pharmaceuticals' EBIT had a median value of -$99.5 million in 2023 and averaged -$124.4 million.
  • In the last 5 years, Recursion Pharmaceuticals' EBIT plummeted by 153.94% in 2021 and then climbed by 6.12% in 2022.
  • Recursion Pharmaceuticals' EBIT (Quarterly) stood at -$65.0 million in 2021, then grew by 6.12% to -$61.0 million in 2022, then slumped by 62.23% to -$98.9 million in 2023, then slumped by 85.76% to -$183.8 million in 2024, then crashed by 75.08% to -$172.2 million in 2025.
  • Its last three reported values are -$172.2 million in Q3 2025, -$176.2 million for Q2 2025, and -$191.4 million during Q1 2025.